Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...

New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates. In this episode, experts examine combination ...

Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality worldwide. While significant advances have been achieved with ...

Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE ...

Pelabresib plus Jakafi significantly reduced spleen volume and improved symptoms in myelofibrosis patients compared to Jakafi alone, with sustained benefits at 96 weeks. The combination therapy showed ...

(a) Schematic of IHoM and IHeM models. NC: neutral cells; AC: cells carrying antigen mutations; IC: immune-recognizable cells; EC: immune-escaped cells. (b) Response of IHoM and IHeM to monotherapies ...

Congruence between circulating tumor DNA and radiographic response during treatment of advanced sarcoma patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of inhibitor ...